Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1993 Jul;37(4):255–263. doi: 10.1007/BF01518520

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

Gail D Lewis 1,✉, Irene Figari 1, Brian Fendly 1, Wai Lee Wong 1, Paul Carter 1, Cori Gorman 1, H Michael Shepard 1
PMCID: PMC11038979  PMID: 8102322

Abstract

The HER2 protooncogene encodes a receptor tyrosine kinase, p185HER2. The overexpression of p185HER2 has been associated with a worsened prognosis in certain human cancers. In the present work we have screened a variety of different tumor cell lines for p185HER2 expression using both enzyme-linked immunosorbent and fluorescence-activated cell sorting assays employing murine monoclonal antibodies directed against the extracellular domain of the receptor. Increased levels of p185HER2 were found in breast (5/9), ovarian (1/6), stomach (2/3) and colorectal (5/16) carcinomas, whereas all kidney and submaxillary adenocarcinoma cell lines tested were negative. Some monoclonal antibodies directed against the extracellular domain of p185HER2 inhibited growth in monolayer culture of breast and ovarian tumor cell lines overexpressing p185HER2, but had no effect on the growth of colon or gastric adenocarcinomas expressing increased levels of this receptor. The most potent growth-inhibitory anti-p185HER2 monoclonal antibody in monolayer culture, designated mumAb 4D5 (a murine IgG1κ antibody), was also tested in soft-agar growth assays for activity against p185HER2-overexpressing tumor cell lines of each type, with similar results. In order to increase the spectrum of tumor types potentially susceptible to monoclonal antibody-mediated anti-p185HER2 therapies, to decrease potential immunogenicity issues with the use of murine monoclonal antibodies for human therapy, and to provide the potential for antibody-mediated cytotoxic activity, a mouse/human chimeric 4D5 (chmAb 4D5) and a “humanized” 4D5 (rhu)mAb 4D5 HER2 antibody were constructed. Both engineered antibodies, in combination with human peripheral blood mononuclear cells, elicited antibody-dependent cytotoxic responses in accordance with the level of p185HER2 expression. Since this cytotoxic activity is independent of sensitivity to mumAb 4D5, the engineered monoclonal antibodies expand the potential target population for antibody-mediated therapy of human cancers characterized by the overexpression of p185HER2.

Key words: p185HER2, Monoclonal antibodies, Growth inhibition, Cytotoxicity

References

  • 1.Aasland R, Lillehaug JR, Hale R, et al. Expression of oncogenes in thyroid tumors: coexpression of c-erbB2/neu and c-erbB. Br J Cancer. 1988;57:358–363. doi: 10.1038/bjc.1988.82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Akiyama T, Sudo C, Ogawara H, et al. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science. 1986;232:1644–1646. doi: 10.1126/science.3012781. [DOI] [PubMed] [Google Scholar]
  • 3.Benz CC, Scott GK, Sarup JC, et al. Tamoxifen resistance associated with p185HER2 overexpression in human breast cancer cells transfected with HER2/neu . Proc Am Assoc Cancer Res. 1991;32:211. [Google Scholar]
  • 4.Berchuck A, Kamel A, Whitaker R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 1990;50:4087–4091. [PubMed] [Google Scholar]
  • 5.Berchuck A, Rodriguez G, Kinney RB, et al. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage discase. Am J Obstet, Gynecol. 1991;164:15–21. doi: 10.1016/0002-9378(91)90615-x. [DOI] [PubMed] [Google Scholar]
  • 6.Berger MS, Locher GW, Saurer S, et al. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res. 1988;48:1238–1243. [PubMed] [Google Scholar]
  • 7.Bonilla M, Ramirez M, Lopez-Cueto J, et al. In vivo amplification and rearrangement of c-myc oncogene in human breast tumors. JNCI. 1988;80:665–671. doi: 10.1093/jnci/80.9.665. [DOI] [PubMed] [Google Scholar]
  • 8.Borst MP, Baker VV, Dixon D, et al. Oncogene alterations in endometrial cancer. Gynecol Oncol. 1990;38:364–366. doi: 10.1016/0090-8258(90)90074-u. [DOI] [PubMed] [Google Scholar]
  • 9.Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984;224:1121–1124. doi: 10.1126/science.6719137. [DOI] [PubMed] [Google Scholar]
  • 10.Brüderlein S, van der Bosch K, Schlag P, et al. Cytogenetics and DNA amplification in colorectal cancers. Genes Chromosomes Cancer. 1990;2:63–70. doi: 10.1002/gcc.2870020112. [DOI] [PubMed] [Google Scholar]
  • 11.Carter P, Presta L, Gorman CM, et al (1993) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA (in press) [DOI] [PMC free article] [PubMed]
  • 12.Coussens L, Yang-Feng TL, Liao Y-C, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location withneu oncogene. Science. 1985;230:1132–1139. doi: 10.1126/science.2999974. [DOI] [PubMed] [Google Scholar]
  • 13.Drebin JA, Link VC, Stern DF, et al. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell. 1985;41:695–706. doi: 10.1016/s0092-8674(85)80050-7. [DOI] [PubMed] [Google Scholar]
  • 14.Drebin JA, Link VC, Greene MI. Monoclonal antibodies specific for theneu oncogene product directly mediate anti-tumor effects in vivo. Oncogene. 1988;2:387–394. [PubMed] [Google Scholar]
  • 15.Drebin JA, Link VC, Greene MI. Monoclonal antibodies reactive with distinct domains of theneu oncogene-encoded p185 molecule exert synergistic antitumor effects in vivo. Oncogene. 1988;2:273–277. [PubMed] [Google Scholar]
  • 16.Fendly BF, Winget M, Hudziak RM, et al. Characterization of monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res. 1990;50:1550–1558. [PubMed] [Google Scholar]
  • 17.Fernandez-Pol JA. Epidermal growth factor receptor of A431 cells. Characterization of a monoclonal anti-receptor antibody noncompetitive agonist of epidermal growth factor action. J Biol Chem. 1985;260:5003–5011. [PubMed] [Google Scholar]
  • 18.Freeman MR, Washecka R, Chung LWK. Aberrant expression of epidermal growth factor receptor and HER-2 (erbB-2) messenger RNAs in human renal cancers. Cancer Res. 1989;49:6221–6225. [PubMed] [Google Scholar]
  • 19.Fukushige S-I, Matsubara K-I, Yoshida M, et al. Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol. 1986;6:955–958. doi: 10.1128/mcb.6.3.955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Guérin M, Barrois M, Terrier M-J, et al. Overexpression of either c-myc or c-erbB-2/neu protooncogenes in human breast carcinomas: correlation with poor prognosis. Oncogene Res. 1988;3:21–31. [PubMed] [Google Scholar]
  • 21.Guérin M, Gabillot M, Mathieu M-C, et al. Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer. 1989;43:201–208. doi: 10.1002/ijc.2910430205. [DOI] [PubMed] [Google Scholar]
  • 22.Hama-Schroff RW, Foon KA, Beatty SM, et al. Human antimurine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res. 1985;45:879–885. [PubMed] [Google Scholar]
  • 23.Hudziak RM, Lewis GD, Shalaby MR, et al. Amplified expression of the HER2/erbB-2 oncogene induces resistance to tumor necrosis factor α in NIH 3T3 cells. Proc Natl Acad Sci USA. 1988;85:5102–5106. doi: 10.1073/pnas.85.14.5102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Hudziak RM, Lewis GD, Winget M, et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol. 1989;9:1165–1172. doi: 10.1128/mcb.9.3.1165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Hynes NE, Gerber HA, Saurer S, et al. Overexpression of the c-erbB-2 protein in human breast tumor cell lines. J Cell Biochem. 1989;39:167–173. doi: 10.1002/jcb.240390208. [DOI] [PubMed] [Google Scholar]
  • 26.Johnson BE, Makuch RW, Simmons AD, et al. myc family DNA amplification in small cell lung cancer patients tumors and corresponding cell lines. Cancer Res. 1988;48:5163–5166. [PubMed] [Google Scholar]
  • 27.Junghans RP, Walmann TA, Landolfi NF, et al. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res. 1990;50:1495–1502. [PubMed] [Google Scholar]
  • 28.Kameda T, Yasui W, Yoshida K, et al. Expression oferbB2 in human gastric carcinomas: relationship between p185erbB2 expression and gene amplification. Cancer Res. 1990;50:8002–8009. [PubMed] [Google Scholar]
  • 29.Kern JA, Schwartz DA, Nordberg JE, et al. p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res. 1990;50:5184–5191. [PubMed] [Google Scholar]
  • 30.King CR, Kraus MN, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science. 1985;229:974–976. doi: 10.1126/science.2992089. [DOI] [PubMed] [Google Scholar]
  • 31.Krauss MH, Popescu NC, Amsbaugh SC, et al. Overexpression of the EGF receptor-related proto-oncogeneerbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J. 1987;6:605–610. doi: 10.1002/j.1460-2075.1987.tb04797.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Kraus MH, Issing W, Miki T, et al. Isolation and characterization ofERBB3, a third member of the “ERBB”/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc. Natl Acad Sci. USA. 1989;86:9193–9197. doi: 10.1073/pnas.86.23.9193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Lee W-H, Murphree AL, Benedict WF. Expression of the N-myc gene in primary retinoblastoma. Nature. 1984;309:458–460. doi: 10.1038/309458a0. [DOI] [PubMed] [Google Scholar]
  • 34.Liberman TA, Nusbaum HR, Razon N, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human tumors of glial origin. Nature. 1985;313:144–147. doi: 10.1038/313144a0. [DOI] [PubMed] [Google Scholar]
  • 35.Lichtenstein A, Berenson J, Gera JF, et al. Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokineactivated killer cells: correlation with expression ofHER2/neu oncogenes. Cancer Res. 1990;50:7364–7370. [PubMed] [Google Scholar]
  • 36.Little CD, Nau MM, Carney DN, et al. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature. 1983;306:194–196. doi: 10.1038/306194a0. [DOI] [PubMed] [Google Scholar]
  • 37.Liu AY, Robinson RR, Hellström KE, et al. Chimeric mousehuman IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci USA. 1987;84:3439–3443. doi: 10.1073/pnas.84.10.3439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Merlino GT, Xu Y-H, Ishii S, et al. Amplified and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells. Science. 1984;224:417–419. doi: 10.1126/science.6200934. [DOI] [PubMed] [Google Scholar]
  • 39.Moriyama M, Akiyama T, Yamamoto T, et al. Expression of C-ERBB-2 gene product in urinary bladder cancer. J Urol. 1991;145:423–427. doi: 10.1016/s0022-5347(17)38356-8. [DOI] [PubMed] [Google Scholar]
  • 40.Park J-B, Rhim JS, Park S-C, et al. Amplification, overexpression and rearrangement of theerbB-2 protooncogene in primary human stomach carcinomas. Cancer Res. 1989;49:6605–6609. [PubMed] [Google Scholar]
  • 41.Perez R, Pascual M, Macias A, et al. Epidermal growth factor receptors in human breast cancer. Breast Cancer Res Treat. 1984;4:189–193. doi: 10.1007/BF01806484. [DOI] [PubMed] [Google Scholar]
  • 42.Reichmann L, Clark M, Waldmann H, et al. Reshaping human antibodies for therapy. Nature. 1988;332:323–329. doi: 10.1038/332323a0. [DOI] [PubMed] [Google Scholar]
  • 43.Ro J, North SM, Gallick GE, et al. Amplified and overexpressed epidermal growth factor receptor gene in uncultured primary human breast carcinoma. Cancer Res. 1988;48:161–164. [PubMed] [Google Scholar]
  • 44.Sarup JC, Johnson RM, King KL, et al. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul. 1991;1:72–82. [PubMed] [Google Scholar]
  • 45.Schechter AL, Stern DF, Vaidyanathan L, et al. Theneu oncogene: anerbB-related gene encoding a 185,000-Mr tumor antigen. Nature. 1984;312:513–516. doi: 10.1038/312513a0. [DOI] [PubMed] [Google Scholar]
  • 46.Schechter AL, Hung M-C, Vaidyanathan L, et al. Theneu gene: anerbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science. 1985;229:976–978. doi: 10.1126/science.2992090. [DOI] [PubMed] [Google Scholar]
  • 47.Schneider PM, Hung M-C, Chiocca SM, et al. Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res. 1989;49:4968–4971. [PubMed] [Google Scholar]
  • 48.Seeger RC, Brodeur GH, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985;313:1111–1116. doi: 10.1056/NEJM198510313131802. [DOI] [PubMed] [Google Scholar]
  • 49.Semba K, Kamato N, Toyoshima K, et al. A v-erbB-related protooncogene, c-erbB-2 is distinct from the c-erbB-1/epidermal growth factor receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA. 1985;82:6497–6501. doi: 10.1073/pnas.82.19.6497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Seshadri R, Matthews C, Dobrovic A, et al. The significance of oncogene amplification in primary breast cancer. Int J Cancer. 1989;43:270–272. doi: 10.1002/ijc.2910430218. [DOI] [PubMed] [Google Scholar]
  • 51.Shalaby MR, Shepard HM, Presta L, et al. The development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing theHER2 protooncogene. J Exp Med. 1992;175:217–225. doi: 10.1084/jem.175.1.217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Shawler DL, Bartholomew RM, Smith LM, et al. Human immune response to multiple injections of murine monoclonal IgG. J Immunol. 1985;135:1530–1535. [PubMed] [Google Scholar]
  • 53.Sias PE, Kotts CE, Vetterlein D, et al. ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids. J Immunol Methods. 1990;132:73–80. doi: 10.1016/0022-1759(90)90400-p. [DOI] [PubMed] [Google Scholar]
  • 54.Slamon DJ, DeKernion JB, Verma IM, et al. Expression of cellular oncogenes in human malignancies. Science. 1984;224:256–262. doi: 10.1126/science.6538699. [DOI] [PubMed] [Google Scholar]
  • 55.Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182. doi: 10.1126/science.3798106. [DOI] [PubMed] [Google Scholar]
  • 56.Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science. 1989;244:707–712. doi: 10.1126/science.2470152. [DOI] [PubMed] [Google Scholar]
  • 57.Stern DF, Heffernan PA, Weinberg RA. p185, a product of theneu protooncogene, is a receptorlike protein associated with tyrosine kinase activity. Mol Cell Biol. 1986;6:1729–1740. doi: 10.1128/mcb.6.5.1729. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Tal M, Wetzler M, Josefberg Z, et al. Sporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues. Cancer Res. 1988;48:1517–1520. [PubMed] [Google Scholar]
  • 59.Tandon AK, Clark GM, Cuamness GC, et al. HER2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol. 1989;7:1120–1128. doi: 10.1200/JCO.1989.7.8.1120. [DOI] [PubMed] [Google Scholar]
  • 60.Ullrich A, Coussens L, Hayflick JS, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature. 1984;300:418–425. doi: 10.1038/309418a0. [DOI] [PubMed] [Google Scholar]
  • 61.van de Vijver M, van de Bersselaar R, Devilee P, et al. Amplification of theneu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol. 1987;7:2019–2023. doi: 10.1128/mcb.7.5.2019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.van de Vijver MJ, Peterse JL, Mool WJ, et al. Neu protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med. 1988;319:1239–1245. doi: 10.1056/NEJM198811103191902. [DOI] [PubMed] [Google Scholar]
  • 63.Venter DJ, Kumar S, Tuzi NL, et al. Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification. Lancet. 1987;2:69–72. doi: 10.1016/s0140-6736(87)92736-x. [DOI] [PubMed] [Google Scholar]
  • 64.Weinberg RA. ras oncogenes and the molecular mechanisms of carcinogenesis. Blood. 1984;64:1143–1145. [PubMed] [Google Scholar]
  • 65.Williams TN, Weiner DB, Greene MI, et al. Expression of c-erbB-2 in human pancreatic adenocarcinomas. Pathobiology. 1991;59:46–52. doi: 10.1159/000163614. [DOI] [PubMed] [Google Scholar]
  • 66.Wright C, Angus B, Nicholson S, et al. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 1989;49:2087–2090. [PubMed] [Google Scholar]
  • 67.Yamamoto T, Kamato N, Kawano N, et al. High incidence of amplification of epidermal growth factor receptor gene in human squamous carcinoma cell line. Cancer Res. 1986;46:414–416. [PubMed] [Google Scholar]
  • 68.Yamazaki H, Fukui Y, Ueyama Y, et al. Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erb) in human brain tumors. Mol Cell Biol. 1988;8:1816–1820. doi: 10.1128/mcb.8.4.1816. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Yao M, Shuin T, Misaki H, et al. Enhanced expression of c-myc and epidermal growth factor receptor (c-erbB1) genes in primary human renal cancer. Cancer Res. 1988;48:6753–6757. [PubMed] [Google Scholar]
  • 70.Yokota J, Yamamoto T, Miyajima N, et al. Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene. 1988;2:283–287. [PubMed] [Google Scholar]
  • 71.Yonemura Y, Ninomiya I, Yamaguchi A, et al. Evaluation of immunorcactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res. 1991;51:1034–1038. [PubMed] [Google Scholar]
  • 72.Zhou D, Battifora H, Yokota J, et al. Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer. Cancer Res. 1987;47:6123–6125. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES